Statin liver safety in non‐alcoholic fatty liver disease: A systematic review and metanalysis
| Autor: | Arianna Pani, Arianna Di Rocco, Danilo Menichelli, Gianluca Gazzaniga, Daniele Pastori, Alessio Farcomeni, Francesco Baratta, Laura D'Erasmo, Maria Del Ben, Francesco Angelico |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
safety
medicine.medical_specialty Statin ALT medicine.drug_class Aspartate transaminase Disease liver digestive system 030226 pharmacology & pharmacy Gastroenterology statins 03 medical and health sciences 0302 clinical medicine Non-alcoholic Fatty Liver Disease NAFLD Internal medicine medicine Humans Pharmacology (medical) Aspartate Aminotransferases 030212 general & internal medicine AST Pharmacology biology medicine.diagnostic_test business.industry Fatty liver nutritional and metabolic diseases Alanine Transaminase Non alcoholic gamma-Glutamyltransferase Statin treatment medicine.disease digestive system diseases GGT Alanine transaminase biology.protein Hydroxymethylglutaryl-CoA Reductase Inhibitors Settore SECS-S/01 business Liver function tests |
| Zdroj: | British Journal of Clinical Pharmacology. 88:441-451 |
| ISSN: | 1365-2125 0306-5251 |
| DOI: | 10.1111/bcp.14943 |
| Popis: | Aims Statin liver safety in non-alcoholic fatty liver disease (NAFLD) patients is not well defined. We analysed differences in liver function tests, including alanine transaminase aminotransferase (ALT), aspartate transaminase (AST) and gamma-glutamyl transpeptidase (GGT) in NAFLD patients treated or not treated with statins. Methods We performed a systematic review of MEDLINE via PubMed and EMBASE databases and metanalysis of clinical studies investigating levels of ALT, AST and GGT in NAFLD according to statin treatment. Mean difference (MD) and percentage MD were calculated between the two groups. Results We included 22 studies with 2345 NAFLD patients. Overall, 16 were before-after interventional, five were cross-sectional and one was combined cross-sectional/interventional study. In all interventional studies, except one, patients had raised ALT, AST and GGT at baseline. Interventional studies showed reduced ALT values with an MD reduction of -27.2 U/L (95% CI -35.25/-19.15) and a percentage MD reduction of -35.41% (95% CI -44.78/-26.04). Also, AST values were reduced after statin treatment in interventional studies with an MD of -18.82 U/L (95% CI -25.63/-12.02) (percentage -31.78%, 95% CI -41.45/-22.11). Similarly, GGT levels were reduced after statin treatment with an MD of -19.93 U/L (95% CI -27.10/-12.77) (percentage -25.57%, 95% CI -35.18/-15.97). Cross-sectional studies showed no difference in AST and GGT values between patients treated with and without statins. Conclusion In interventional studies, ALT, AST and GGT were reduced after statin treatment with a percentage mean difference of -35.41%, -31.78% and -25.57%, respectively, while observational studies showed a null effect, suggesting liver safety of statins in NAFLD patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text